WO2004043480A3 - Intraocular administration of cyclosporin a for the treatment of macular degeneration, retinopathy or retinitis pigmentosa - Google Patents
Intraocular administration of cyclosporin a for the treatment of macular degeneration, retinopathy or retinitis pigmentosa Download PDFInfo
- Publication number
- WO2004043480A3 WO2004043480A3 PCT/US2003/028315 US0328315W WO2004043480A3 WO 2004043480 A3 WO2004043480 A3 WO 2004043480A3 US 0328315 W US0328315 W US 0328315W WO 2004043480 A3 WO2004043480 A3 WO 2004043480A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cyclosporin
- retinopathy
- treatment
- macular degeneration
- retinitis pigmentosa
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003301961A AU2003301961A1 (en) | 2002-11-07 | 2003-09-10 | Intraocular administration of cyclosporin a for the treatment of macular degeneration, retinopathy or retinitis pigmentosa |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/289,772 | 2002-11-07 | ||
US10/289,772 US7354574B2 (en) | 2002-11-07 | 2002-11-07 | Treatment of ocular disease |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004043480A2 WO2004043480A2 (en) | 2004-05-27 |
WO2004043480A3 true WO2004043480A3 (en) | 2004-07-29 |
Family
ID=32228929
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/028315 WO2004043480A2 (en) | 2002-11-07 | 2003-09-10 | Intraocular administration of cyclosporin a for the treatment of macular degeneration, retinopathy or retinitis pigmentosa |
Country Status (3)
Country | Link |
---|---|
US (1) | US7354574B2 (en) |
AU (1) | AU2003301961A1 (en) |
WO (1) | WO2004043480A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8871772B2 (en) | 2008-05-27 | 2014-10-28 | Ampio Pharmaceuticals, Inc. | Therapeutic methods and compounds |
US9233113B2 (en) | 2009-06-22 | 2016-01-12 | Ampio Pharmaceuticals, Inc. | Method for treatment of diseases |
US9351979B2 (en) | 2012-12-19 | 2016-05-31 | Ampio Pharmaceuticals, Inc. | Methods of treatment of diseases |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070027537A1 (en) * | 2002-08-02 | 2007-02-01 | David Castillejos | Method and intra-sclera implant for treatment of glaucoma and presbyopia |
WO2004027027A2 (en) * | 2002-09-18 | 2004-04-01 | Trustees Of The University Of Pennsylvania | Method of inhibiting choroidal neovascularization |
US7354574B2 (en) | 2002-11-07 | 2008-04-08 | Advanced Ocular Systems Limited | Treatment of ocular disease |
US8404269B2 (en) * | 2003-04-11 | 2013-03-26 | Michael Snyder | Sustained release implantable eye device |
US7083802B2 (en) | 2003-07-31 | 2006-08-01 | Advanced Ocular Systems Limited | Treatment of ocular disease |
AU2004274026A1 (en) * | 2003-09-18 | 2005-03-31 | Macusight, Inc. | Transscleral delivery |
US7087237B2 (en) * | 2003-09-19 | 2006-08-08 | Advanced Ocular Systems Limited | Ocular solutions |
US7083803B2 (en) | 2003-09-19 | 2006-08-01 | Advanced Ocular Systems Limited | Ocular solutions |
AU2005209201B2 (en) | 2004-01-20 | 2010-06-03 | Allergan, Inc. | Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid |
NZ551955A (en) | 2004-06-23 | 2010-08-27 | Revision Therapeutics Inc | Methods and compositions for treating ophthalmic conditions with retinyl derivatives |
CA2572592C (en) | 2004-07-02 | 2015-09-08 | Eliot Lazar | Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device |
WO2006003519A2 (en) * | 2004-07-02 | 2006-01-12 | Novagali Pharma Sa | Use of emulsions for intra: and periocular injection |
US8541413B2 (en) * | 2004-10-01 | 2013-09-24 | Ramscor, Inc. | Sustained release eye drop formulations |
US20080038316A1 (en) * | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
US9993558B2 (en) | 2004-10-01 | 2018-06-12 | Ramscor, Inc. | Sustained release eye drop formulations |
JP5682991B2 (en) * | 2004-10-01 | 2015-03-11 | ラムズコア, インコーポレイテッド | Convenient implantable sustained release drug formulation |
MX2007004030A (en) * | 2004-10-04 | 2008-01-14 | Cellgate Inc | Polyamine analogs as therapeutic agents for ocular diseases. |
EP1804788A4 (en) * | 2004-10-25 | 2008-05-21 | Sirion Therapeutics Inc | Detection and analysis of ophthalmically-relevant fluorescent molecules |
KR20070091283A (en) * | 2004-11-04 | 2007-09-10 | 시리온 테라퓨틱스, 인크. | Modulators of retinol-retinol binding protein(rbp)-transthyretin(ttr) complex formation |
CA2638753A1 (en) | 2004-12-08 | 2006-06-15 | Sirion Therapeutics, Inc. | Methods, assays and compositions for treating retinol-related diseases |
EP1845984B1 (en) | 2005-01-20 | 2013-01-09 | Institute for Molecular Medicine, Inc. | Methylphenidate derivatives and uses of them |
US8663639B2 (en) * | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
ES2564194T3 (en) * | 2005-02-09 | 2016-03-18 | Santen Pharmaceutical Co., Ltd. | Liquid formulations for the treatment of diseases or ailments |
UA81382C2 (en) * | 2005-07-11 | 2007-12-25 | Composition for treating retinol-related diseases by modulation of retinol binding | |
EP2462959B1 (en) | 2005-07-12 | 2016-06-22 | Ampio Pharmaceuticals, Inc. | Methods and products for treatment of diseases |
US20080262415A1 (en) * | 2005-07-18 | 2008-10-23 | Peyman Gholam A | Enhanced wound healing |
WO2007011880A2 (en) | 2005-07-18 | 2007-01-25 | Minu, L.L.C. | Enhanced ocular neuroprotection/neurostimulation |
US9839667B2 (en) | 2005-10-14 | 2017-12-12 | Allergan, Inc. | Prevention and treatment of ocular side effects with a cyclosporin |
US7745400B2 (en) * | 2005-10-14 | 2010-06-29 | Gregg Feinerman | Prevention and treatment of ocular side effects with a cyclosporin |
AU2006304143A1 (en) * | 2005-10-14 | 2007-04-26 | Allergan, Inc. | Prevention and treatment of drug-associated ocular side effects with a cyclosporin |
PL1959925T3 (en) * | 2005-12-02 | 2017-05-31 | (Osi) Eyetech, Inc. | Controlled release microparticles |
KR20140093764A (en) | 2006-02-09 | 2014-07-28 | 산텐 세이야꾸 가부시키가이샤 | Stable formulations, and methods of their preparation and use |
DK2001466T3 (en) | 2006-03-23 | 2016-02-29 | Santen Pharmaceutical Co Ltd | LOW-DOSAGE RAPAMYCINE FOR TREATMENT OF VASCULAR PERMEABILITY-RELATED DISEASES |
EP3449873A1 (en) | 2006-03-31 | 2019-03-06 | Mati Therapeutics Inc. | Drug delivery structures and compositions for nasolacrimal system |
WO2008001380A2 (en) * | 2006-06-28 | 2008-01-03 | Yeda Research And Development Co. Ltd. | Method of treatment of age-related macular degeneration |
US9561178B2 (en) * | 2006-07-25 | 2017-02-07 | Allergan, Inc. | Cyclosporin compositions |
US20080265343A1 (en) * | 2007-04-26 | 2008-10-30 | International Business Machines Corporation | Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof |
EP2205193A2 (en) | 2007-09-07 | 2010-07-14 | QLT Plug Delivery, Inc. | Lacrimal implant detection |
MX2010004366A (en) * | 2007-11-05 | 2010-05-05 | Bausch & Lomb | Water-immiscible materials as vehicles for drug delivery. |
US20090196905A1 (en) * | 2008-02-06 | 2009-08-06 | Spada Lon T | Stabilization of mitochondrial membranes in ocular diseases and conditions |
CN107412722A (en) | 2009-08-24 | 2017-12-01 | 康德生物医疗技术公司 | For preventing or treating the method and composition of eye disease |
KR101351181B1 (en) | 2010-05-11 | 2014-01-14 | 가천대학교 산학협력단 | Method for inhibiting cell death induction by inhibiting synthesis or secretion of AGE-albumin in mononuclear phagocyte system |
WO2011161295A2 (en) * | 2010-06-23 | 2011-12-29 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | Use of anticalcineurin compounds for the treatment of pathologies involving ocular neovascularisation |
CA2810844C (en) | 2010-09-07 | 2017-03-21 | Dmi Acquisition Corp. | Diketopiperazine compositions for the treatment of metabolic syndrome and related conditions |
US9974685B2 (en) | 2011-08-29 | 2018-05-22 | Mati Therapeutics | Drug delivery system and methods of treating open angle glaucoma and ocular hypertension |
EP2750660B1 (en) | 2011-08-29 | 2016-10-12 | Mati Therapeutics Inc. | Sustained release delivery of active agents to treat glaucoma and ocular hypertension |
JP6275707B2 (en) | 2012-06-20 | 2018-02-07 | フランク・グー | Mucoadhesive nanoparticle delivery system |
US9878000B2 (en) * | 2012-06-20 | 2018-01-30 | University Of Waterloo | Mucoadhesive nanoparticle composition comprising immunosuppresant and methods of use thereof |
US9694050B2 (en) | 2012-10-21 | 2017-07-04 | University Of Rochester | THY1 (CD90) as a novel therapy to control adipose tissue accumulation |
GB201522441D0 (en) | 2015-12-18 | 2016-02-03 | Midatech Pharma Wales Ltd | Sustained release cyclosporine-loaded microparticles |
WO2017173327A1 (en) | 2016-03-31 | 2017-10-05 | The Schepens Eye Research Institute, Inc. | Endomucin inhibitor as an anti-angiogenic agent |
WO2018093797A1 (en) | 2016-11-15 | 2018-05-24 | The Schepens Eye Research Institute, Inc. | Compositions and methods for the treatment of aberrant angiogenesis |
WO2019070917A1 (en) | 2017-10-03 | 2019-04-11 | The Schepens Eye Research Institute, Inc. | Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same |
EP3710008A4 (en) | 2017-11-14 | 2021-08-25 | The Schepens Eye Research Institute, Inc. | Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition |
WO2019191700A1 (en) * | 2018-03-29 | 2019-10-03 | Mati Therapeutics | Ophthalmic drug sustained release formulation and uses for dry eye syndrome treatment |
WO2020171889A1 (en) | 2019-02-19 | 2020-08-27 | University Of Rochester | Blocking lipid accumulation or inflammation in thyroid eye disease |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5294604A (en) * | 1989-12-20 | 1994-03-15 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating ocular diseases by periocular administration of cyclosporine A or G |
US5773019A (en) * | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
WO2002085928A2 (en) * | 2001-04-20 | 2002-10-31 | Debiopharm S.A. | Modified cyclosporine which can be used as a pro-drug and use thereof |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4093709A (en) | 1975-01-28 | 1978-06-06 | Alza Corporation | Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates) |
US4180646A (en) | 1975-01-28 | 1979-12-25 | Alza Corporation | Novel orthoester polymers and orthocarbonate polymers |
US4131648A (en) | 1975-01-28 | 1978-12-26 | Alza Corporation | Structured orthoester and orthocarbonate drug delivery devices |
US4079038A (en) | 1976-03-05 | 1978-03-14 | Alza Corporation | Poly(carbonates) |
US4310518A (en) * | 1979-10-31 | 1982-01-12 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
US4304767A (en) | 1980-05-15 | 1981-12-08 | Sri International | Polymers of di- (and higher functionality) ketene acetals and polyols |
EP0107425A3 (en) | 1982-10-21 | 1984-11-14 | Johnson Matthey Public Limited Company | Radiation pattern change detection |
IT1194564B (en) * | 1983-04-18 | 1988-09-22 | Acraf | USE OF BENDAZAC AND ITS SALTS IN THE TREATMENT OF PIGMENTAL RETINITIS |
JP2577049B2 (en) | 1987-06-04 | 1997-01-29 | 三共株式会社 | Cyclosporine preparation |
KR920003601B1 (en) | 1987-09-03 | 1992-05-04 | 유니버시티 어브 죠지아 리서취 화운데이션 인코포레이티드 | Ocular cyclosporin composition |
US4946931A (en) | 1989-06-14 | 1990-08-07 | Pharmaceutical Delivery Systems, Inc. | Polymers containing carboxy-ortho ester and ortho ester linkages |
DE69016515T2 (en) | 1989-07-05 | 1995-06-08 | Fujisawa Pharmaceutical Co | Aqueous liquid agent for external use. |
IL102414A (en) | 1991-07-25 | 1996-08-04 | Univ Louisville Res Found | Pharmaceutical compositions for treating ocular inflammation comprising rapamycin |
JPH0710752A (en) | 1993-06-23 | 1995-01-13 | Tokushu Meneki Kenkyusho:Kk | Novel medicinal composition for treating allergic and autoimmune diseases |
US5788687A (en) | 1994-02-01 | 1998-08-04 | Caphco, Inc | Compositions and devices for controlled release of active ingredients |
US5457182A (en) | 1994-02-15 | 1995-10-10 | Merck & Co., Inc. | FK-506 cytosolic binding protein, FKBP12.6 |
US6179817B1 (en) | 1995-02-22 | 2001-01-30 | Boston Scientific Corporation | Hybrid coating for medical devices |
US6413536B1 (en) | 1995-06-07 | 2002-07-02 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system and medical or surgical device |
JPH0930966A (en) | 1995-07-24 | 1997-02-04 | Gakuzo Tamura | New pharmaceutical preparation for eye |
US5968543A (en) | 1996-01-05 | 1999-10-19 | Advanced Polymer Systems, Inc. | Polymers with controlled physical state and bioerodibility |
US6238799B1 (en) | 1996-02-09 | 2001-05-29 | Surface Solutions Laboratories, Inc. | Articles prepared from water-based hydrophilic coating compositions |
ES2243978T3 (en) | 1996-02-13 | 2005-12-01 | G.D. SEARLE & CO. | COMPOSITIONS THAT INCLUDE AN INHIBITOR OF CYCLLOXYGENASA-2 AND AN ANTAGONIST OF THE RECEIVER OF LEUCOTRENE B4. |
JPH09315954A (en) | 1996-05-30 | 1997-12-09 | Kita:Kk | Medicine for preventing opacity of ocular tissue after ophthalmic operation |
US5952371A (en) | 1996-10-16 | 1999-09-14 | Merck & Co., Inc. | Triterpene derivatives with immunosuppressant activity |
AUPO427196A0 (en) | 1996-12-19 | 1997-01-23 | University Of Sydney, The | A method for preventing or controlling cataract |
JPH10218787A (en) | 1997-02-06 | 1998-08-18 | Akio Okamoto | Ophthalmic composition based on neurotrophic factor |
US6670398B2 (en) | 1997-05-14 | 2003-12-30 | Atherogenics, Inc. | Compounds and methods for treating transplant rejection |
JPH1180026A (en) | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | New immunosuppressant, its use and its identification |
ZA989885B (en) | 1997-10-31 | 1999-05-05 | Abbott Lab | Use of macrolides for the treatment of cancer and macular degeneration |
CZ287497B6 (en) | 1997-12-30 | 2000-12-13 | Galena, A. S. | Topic eye preparations containing immunosuppressive substances |
JP2002503692A (en) | 1998-02-23 | 2002-02-05 | 藤沢薬品工業株式会社 | Use of macrolides for glaucoma treatment |
DE19810655A1 (en) | 1998-03-12 | 1999-09-16 | Univ Eberhard Karls | Pharmaceutical composition containing cyclosporin A suitable for topical administration for treating disorders of skin, mucosa and eyes |
EP1067926A2 (en) * | 1998-04-06 | 2001-01-17 | Fujisawa Pharmaceutical Co., Ltd. | Immunosuppressive imidazole derivatives and their combination preparations with tacrolimus or cyclosporins |
CA2326222C (en) | 1998-04-27 | 2008-09-23 | Fujisawa Pharmaceutical Co., Ltd. | Medicinal compositions |
US6225348B1 (en) * | 1998-08-20 | 2001-05-01 | Alfred W. Paulsen | Method of treating macular degeneration with a prostaglandin derivative |
US6864232B1 (en) | 1998-12-24 | 2005-03-08 | Sucampo Ag | Agent for treating visual cell function disorder |
US6462071B1 (en) * | 2000-03-02 | 2002-10-08 | Vitreo-Retinal Technologies, Inc. | Agents for intravitreal administration to treat or prevent disorders of the eye |
US6239113B1 (en) | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
US6254860B1 (en) | 1999-04-13 | 2001-07-03 | Allergan Sales, Inc. | Ocular treatment using cyclosporin-A derivatives |
IL146162A0 (en) | 1999-04-30 | 2002-07-25 | R Tech Ueno Ltd | Macrolide compounds for the treatment of dry eye |
US7063857B1 (en) | 1999-04-30 | 2006-06-20 | Sucampo Ag | Use of macrolide compounds for the treatment of dry eye |
US6482799B1 (en) | 1999-05-25 | 2002-11-19 | The Regents Of The University Of California | Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial |
CN1378445B (en) | 1999-08-06 | 2013-02-06 | 得克萨斯系统大学评议会 | Drug releasing biodegradable fiber implant |
JP2001064198A (en) | 1999-08-24 | 2001-03-13 | Teika Seiyaku Kk | Therapeutic agent for corneal disease |
EP1225879A2 (en) | 1999-10-22 | 2002-07-31 | Orbon Corporation | Ophthalmic formulation of dopamine antagonists |
US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
US6489335B2 (en) | 2000-02-18 | 2002-12-03 | Gholam A. Peyman | Treatment of ocular disease |
US20030018044A1 (en) | 2000-02-18 | 2003-01-23 | Peyman Gholam A. | Treatment of ocular disease |
ATE250924T1 (en) | 2000-04-07 | 2003-10-15 | Medidom Lab | EYE MEDICINAL CONTAINING CYCLOSPORINE, HYALURONIC ACID AND POLYSORBATES |
AU6110301A (en) | 2000-04-29 | 2001-11-12 | Univ Iowa Res Found | Diagnostics and therapeutics for macular degeneration-related disorders |
US6613355B2 (en) | 2000-05-11 | 2003-09-02 | A.P. Pharma, Inc. | Semi-solid delivery vehicle and pharmaceutical compositions |
CN1127955C (en) | 2000-07-07 | 2003-11-19 | 中山医科大学中山眼科中心 | Medicine for treating immune relative disease of anterior chamber and surface of eye |
CN1204919C (en) | 2000-08-30 | 2005-06-08 | 中国科学院化学研究所 | Long-acting intra-ocular release system of cyclosporin |
WO2002024234A2 (en) | 2000-09-20 | 2002-03-28 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
US6534693B2 (en) | 2000-11-06 | 2003-03-18 | Afmedica, Inc. | Surgically implanted devices having reduced scar tissue formation |
US6440942B1 (en) | 2000-12-22 | 2002-08-27 | Enanta Pharmaceuticals, Inc. | 14-membered macrolides derived from leucomycins |
US6462026B1 (en) | 2001-02-16 | 2002-10-08 | Enanta Pharmaceuticals, Inc. | Bicyclic leucomycins |
US6713081B2 (en) * | 2001-03-15 | 2004-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Ocular therapeutic agent delivery devices and methods for making and using such devices |
US6436906B1 (en) | 2001-04-02 | 2002-08-20 | Enanta Pharmaceuticals, Inc. | 9-amino-14-membered macrolides derived from leucomycins |
AR033151A1 (en) | 2001-04-12 | 2003-12-03 | Sucampo Pharmaceuticals Inc | AGENT FOR THE TOPICAL OPHTHALMIC TREATMENT OF OCULAR INFLAMMATORY DISEASES |
WO2003004098A1 (en) | 2001-07-06 | 2003-01-16 | Sucampo Ag | Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent |
AR035293A1 (en) | 2001-08-23 | 2004-05-05 | Novartis Ag | OPHTHALMIC COMPOSITION. |
US6524606B1 (en) | 2001-11-16 | 2003-02-25 | Ap Pharma, Inc. | Bioerodible polyorthoesters containing amine groups |
WO2003043650A1 (en) | 2001-11-21 | 2003-05-30 | Sucampo Ag | Use of fk506 and analogues for treating allergic diseases |
BR0117197A (en) | 2001-12-14 | 2004-12-14 | Jagotec Ag | Drug formulation containing cyclosporine application of same |
CN1456350A (en) | 2002-05-10 | 2003-11-19 | 刘继东 | Eye cyclosporin gel |
EP1536793A1 (en) | 2002-08-09 | 2005-06-08 | Sucampo Pharmaceuticals, Inc. | Pharmaceutical compositions comprising fk506 derivatives and the ir use for the treatment of allergic diseases |
WO2004027027A2 (en) | 2002-09-18 | 2004-04-01 | Trustees Of The University Of Pennsylvania | Method of inhibiting choroidal neovascularization |
US7354574B2 (en) | 2002-11-07 | 2008-04-08 | Advanced Ocular Systems Limited | Treatment of ocular disease |
AR042890A1 (en) | 2003-01-16 | 2005-07-06 | Sucampo Pharmaceuticals Inc | METHOD OF DRY EYE TREATMENT WITH AN OPHTHALMIC COMPOSITION CONTAINING A MACROLID COMPOUND |
WO2004096261A1 (en) | 2003-05-02 | 2004-11-11 | Arturo Jimenez Bayardo | Method of preparing an aqueous solution of cyclosporin-a and resulting aqueous solution |
US7083802B2 (en) | 2003-07-31 | 2006-08-01 | Advanced Ocular Systems Limited | Treatment of ocular disease |
AU2004274026A1 (en) | 2003-09-18 | 2005-03-31 | Macusight, Inc. | Transscleral delivery |
US7083803B2 (en) | 2003-09-19 | 2006-08-01 | Advanced Ocular Systems Limited | Ocular solutions |
US7087237B2 (en) | 2003-09-19 | 2006-08-08 | Advanced Ocular Systems Limited | Ocular solutions |
-
2002
- 2002-11-07 US US10/289,772 patent/US7354574B2/en not_active Expired - Fee Related
-
2003
- 2003-09-10 WO PCT/US2003/028315 patent/WO2004043480A2/en not_active Application Discontinuation
- 2003-09-10 AU AU2003301961A patent/AU2003301961A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5294604A (en) * | 1989-12-20 | 1994-03-15 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating ocular diseases by periocular administration of cyclosporine A or G |
US5773019A (en) * | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
WO2002085928A2 (en) * | 2001-04-20 | 2002-10-31 | Debiopharm S.A. | Modified cyclosporine which can be used as a pro-drug and use thereof |
Non-Patent Citations (5)
Title |
---|
APEL A ET AL: "A SUBCONJUNCTIVAL DEGRADABLE IMPLANT FOR CYCLOSPORINE DELIVERY IN CORNEAL TRANSPLANT THERAPY", CURRENT EYE RESEARCH, IRL PRESS, OXFORD, GB, vol. 14, no. 8, August 1995 (1995-08-01), pages 659 - 667, XP001083691, ISSN: 0271-3683 * |
ENYEDI L B ET AL: "An intravitreal device providing sustained release of cyclosporine and dexamethasone.", CURRENT EYE RESEARCH. MAY 1996, vol. 15, no. 5, May 1996 (1996-05-01), pages 549 - 557, XP009031363, ISSN: 0271-3683 * |
ENYEDI L B ET AL: "Pharmacokinetics and toxicity of an intravitreal device providing sustained release of cyclosporine (CsA) and dexamethasone (DEX)", INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE, vol. 35, no. 4, 1994, & ANNUAL MEETING OF THE ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY; SARASOTA, FLORIDA, USA; MAY 1-6, 1994, pages 1906, XP009031364, ISSN: 0146-0404 * |
GARWEG J ET AL: "[Treatment of Goldmann-Favre syndrome with cyclosporin A and bromocriptine]", KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE. SEP 1991, vol. 199, no. 3, September 1991 (1991-09-01), pages 199 - 205, XP009031373, ISSN: 0023-2165 * |
LALLEMAND F ET AL: "Cyclosporine A delivery to the eye: A pharmaceutical challenge", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 56, no. 3, November 2003 (2003-11-01), pages 307 - 318, XP004470466, ISSN: 0939-6411 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8871772B2 (en) | 2008-05-27 | 2014-10-28 | Ampio Pharmaceuticals, Inc. | Therapeutic methods and compounds |
US9522893B2 (en) | 2008-05-27 | 2016-12-20 | Ampio Pharmaceuticals, Inc. | Therapeutic methods and compounds |
US9233113B2 (en) | 2009-06-22 | 2016-01-12 | Ampio Pharmaceuticals, Inc. | Method for treatment of diseases |
US9351979B2 (en) | 2012-12-19 | 2016-05-31 | Ampio Pharmaceuticals, Inc. | Methods of treatment of diseases |
Also Published As
Publication number | Publication date |
---|---|
US20040092435A1 (en) | 2004-05-13 |
WO2004043480A2 (en) | 2004-05-27 |
AU2003301961A8 (en) | 2004-06-03 |
AU2003301961A1 (en) | 2004-06-03 |
US7354574B2 (en) | 2008-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004043480A3 (en) | Intraocular administration of cyclosporin a for the treatment of macular degeneration, retinopathy or retinitis pigmentosa | |
WO2004028477A3 (en) | Methods for treatment and/or prevention of retinal disease | |
WO2007011880A3 (en) | Enhanced ocular neuroprotection/neurostimulation | |
WO2002036162A3 (en) | Compositions for treatment of ocular neovascularization and neural injury | |
WO2006036715A3 (en) | Implant and pressure sensor for glaucoma treatment | |
WO2005011813A3 (en) | Treatment of ocular disease | |
WO2003071986A3 (en) | Method for treating otic disorders | |
WO2007035356A3 (en) | Glaucoma treatment devices and methods | |
EA200501018A1 (en) | OPHTHALMOLOGICAL PREPARATION FOR PREVENTION AND TREATMENT OF PATIENTS WITH DISEASES | |
TW200633709A (en) | Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions | |
CA2582316A1 (en) | Use of inhibitors of jun n-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases | |
TW200744574A (en) | Use of L-carnitine or of alkanoyl L-carnitines for the preparation of a physiological supplement of medicament for ophthalmic use in the form of eye-drops | |
BRPI0506983A (en) | localized eye therapy compositions, preferably comprising triamcinolone acetonide and hyaluronic acid | |
WO2003082081A3 (en) | Use of rom production and release inhibitors to treat and prevent intraocular damage | |
WO2008140052A1 (en) | Prophylactic or therapeutic agent for posterior ocular disease comprising ropinirole or salt thereof as active ingredient | |
CA2440764A1 (en) | Combination of brimonidine and timolol for topical ophthalmic use | |
WO2006047466A3 (en) | Ophthamological drugs | |
WO2009097468A3 (en) | Drug delivery devices, kits and methods therefor | |
WO2007044668A3 (en) | Compstatin and analogs thereof for eye disorders | |
WO2008067040A3 (en) | Method of detecting ocular diseases and pathologic conditions and treatment of same | |
WO2000056354A3 (en) | Methods of using agents that act on the epithelial sheet of a human eye | |
WO2004106378A3 (en) | Method of treating corneal transplant rejection by using vegf antagonists | |
WO2001030380A3 (en) | Methods and compositions for treatment of keratoconus using protease inhibitors | |
WO2007089673A8 (en) | Compositions and methods for treatment of ophthalmic diseases and disorders | |
HK1110768A1 (en) | 5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |